{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T02:53:38Z","timestamp":1773975218325,"version":"3.50.1"},"reference-count":144,"publisher":"Springer Science and Business Media LLC","issue":"31","license":[{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100005440","name":"U.S. Department of Health & Human Services | NIH | Center for Scientific Review","doi-asserted-by":"publisher","award":["5R00CA218891-04"],"award-info":[{"award-number":["5R00CA218891-04"]}],"id":[{"id":"10.13039\/100005440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005440","name":"U.S. Department of Health & Human Services | NIH | Center for Scientific Review","doi-asserted-by":"publisher","award":["1R01CA262822-01"],"award-info":[{"award-number":["1R01CA262822-01"]}],"id":[{"id":"10.13039\/100005440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005440","name":"U.S. Department of Health & Human Services | NIH | Center for Scientific Review","doi-asserted-by":"publisher","award":["R00CA240896"],"award-info":[{"award-number":["R00CA240896"]}],"id":[{"id":"10.13039\/100005440","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | Center for Scientific Review"},{"name":"U.S. Department of Health & Human Services | NIH | Center for Scientific Review"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2022,7,29]]},"DOI":"10.1038\/s41388-022-02406-7","type":"journal-article","created":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T13:03:14Z","timestamp":1657544594000},"page":"3821-3829","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Co-dependencies in the tumor immune microenvironment"],"prefix":"10.1038","volume":"41","author":[{"given":"Peiwen","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6678-503X","authenticated-orcid":false,"given":"Prasenjit","family":"Dey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,11]]},"reference":[{"key":"2406_CR1","unstructured":"Th. Boveri. Jena GF. Zur Frage der Entstehung maligner Tumoren. Science. 1914;40:12."},{"key":"2406_CR2","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1073\/pnas.67.4.1673","volume":"67","author":"PH Duesberg","year":"1970","unstructured":"Duesberg PH, Vogt PK. Differences between the ribonucleic acids of transforming and nontransforming avian tumor viruses. Proc Natl Acad Sci USA. 1970;67:1673\u201380.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2406_CR3","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/260170a0","volume":"260","author":"D Stehelin","year":"1976","unstructured":"Stehelin D, Varmus HE, Bishop JM, Vogt PK. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature. 1976;260:170\u20133.","journal-title":"Nature"},{"key":"2406_CR4","doi-asserted-by":"publisher","first-page":"15259","DOI":"10.1073\/pnas.1521145112","volume":"112","author":"K Bister","year":"2015","unstructured":"Bister K. Discovery of oncogenes: the advent of molecular cancer research. Proc Natl Acad Sci USA. 2015;112:15259\u201360.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2406_CR5","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1073\/pnas.68.4.820","volume":"68","author":"AG Knudson Jr","year":"1971","unstructured":"Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971;68:820\u20133.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2406_CR6","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1097\/PPO.0000000000000127","volume":"21","author":"Z Werb","year":"2015","unstructured":"Werb Z, Lu P. The role of stroma in tumor development. Cancer J. 2015;21:250\u20133.","journal-title":"Cancer J"},{"key":"2406_CR7","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.cell.2009.10.027","volume":"139","author":"KR Levental","year":"2009","unstructured":"Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009;139:891\u2013906.","journal-title":"Cell"},{"key":"2406_CR8","first-page":"1","volume":"3","author":"WB Coley","year":"1910","unstructured":"Coley WB. The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). Proc R Soc Med. 1910;3:1\u201348.","journal-title":"Proc R Soc Med"},{"key":"2406_CR9","unstructured":"Himmelweit F. The collected papers of Paul Ehrlich (Book) 1960."},{"key":"2406_CR10","first-page":"3","volume":"7","author":"FM Burnet","year":"1971","unstructured":"Burnet FM. Immunological surveillance in neoplasia. Transpl Rev. 1971;7:3\u201325.","journal-title":"Transpl Rev"},{"key":"2406_CR11","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991\u20138.","journal-title":"Nat Immunol"},{"key":"2406_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348:69\u201374.","journal-title":"Science"},{"key":"2406_CR13","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1056\/NEJMc1804812","volume":"378","author":"D Zucman","year":"2018","unstructured":"Zucman D, Mellot F, Couderc L. HIV-associated cancers and related diseases. N Engl J Med. 2018;378:2144\u20135.","journal-title":"N Engl J Med"},{"key":"2406_CR14","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.amepre.2013.10.029","volume":"46","author":"MC White","year":"2014","unstructured":"White MC, Holman DM, Boehm JE, Peipins LA, Grossman M, Henley SJ. Age and cancer risk: a potentially modifiable relationship. Am J Prev Med. 2014;46:S7\u201315.","journal-title":"Am J Prev Med"},{"key":"2406_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.pharmthera.2017.03.012","volume":"178","author":"JE Jaspers","year":"2017","unstructured":"Jaspers JE, Brentjens RJ. Development of CAR T cells designed to improve antitumor efficacy and safety. Pharm Ther. 2017;178:83\u201391.","journal-title":"Pharm Ther"},{"key":"2406_CR16","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"DR Leach","year":"1996","unstructured":"Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271:1734\u20136.","journal-title":"Science"},{"key":"2406_CR17","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA. 2002;99:12293\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2406_CR18","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","volume":"11","author":"Y Ishida","year":"1992","unstructured":"Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11:3887\u201395.","journal-title":"EMBO J"},{"key":"2406_CR19","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20:174\u201386.","journal-title":"Nat Rev Cancer"},{"key":"2406_CR20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrc.2017.51","volume":"17","author":"M De Palma","year":"2017","unstructured":"De Palma M, Biziato D, Petrova TV. Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer. 2017;17:457\u201374.","journal-title":"Nat Rev Cancer"},{"key":"2406_CR21","doi-asserted-by":"crossref","unstructured":"Pang L, Khan F, Heimberger AB, Chen P. Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma. Trends Cancer. 2022.","DOI":"10.1016\/j.trecan.2022.04.010"},{"key":"2406_CR22","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","volume":"155","author":"CW Brennan","year":"2013","unstructured":"Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155:462\u201377.","journal-title":"Cell"},{"key":"2406_CR23","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/nature07385","volume":"455","author":"Cancer Genome Atlas Research N.","year":"2008","unstructured":"Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061\u20138.","journal-title":"Nature"},{"key":"2406_CR24","doi-asserted-by":"publisher","first-page":"100186","DOI":"10.1016\/j.xcrm.2020.100186","volume":"2","author":"R Salgia","year":"2021","unstructured":"Salgia R, Pharaon R, Mambetsariev I, Nam A, Sattler M. The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Cell Rep Med. 2021;2:100186.","journal-title":"Cell Rep Med"},{"key":"2406_CR25","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1101\/gad.275776.115","volume":"30","author":"H Ying","year":"2016","unstructured":"Ying H, Dey P, Yao W, Kimmelman AC, Draetta GF, Maitra A, et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2016;30:355\u201385.","journal-title":"Genes Dev"},{"key":"2406_CR26","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/ijc.11681","volume":"109","author":"D Atkins","year":"2004","unstructured":"Atkins D, Breuckmann A, Schmahl GE, Binner P, Ferrone S, Krummenauer F, et al. MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma. Int J Cancer. 2004;109:265\u201373.","journal-title":"Int J Cancer"},{"key":"2406_CR27","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ccell.2019.02.008","volume":"35","author":"W Liao","year":"2019","unstructured":"Liao W, Overman MJ, Boutin AT, Shang X, Zhao D, Dey P, et al. KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer. Cancer Cell. 2019;35:559\u201372. e557","journal-title":"Cancer Cell"},{"key":"2406_CR28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.lungcan.2018.05.009","volume":"121","author":"AT Falk","year":"2018","unstructured":"Falk AT, Yazbeck N, Guibert N, Chamorey E, Paquet A, Ribeyre L, et al. Effect of mutant variants of the KRAS gene on PD-L1 expression and on the immune microenvironment and association with clinical outcome in lung adenocarcinoma patients. Lung Cancer. 2018;121:70\u201375.","journal-title":"Lung Cancer"},{"key":"2406_CR29","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1158\/2159-8290.CD-19-0297","volume":"10","author":"P Dey","year":"2020","unstructured":"Dey P, Li J, Zhang J, Chaurasiya S, Strom A, Wang H, et al. Oncogenic KRAS-driven metabolic reprogramming in pancreatic cancer cells utilizes cytokines from the tumor microenvironment. Cancer Disco. 2020;10:608\u201325.","journal-title":"Cancer Disco"},{"key":"2406_CR30","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.ccr.2012.04.024","volume":"21","author":"Y Pylayeva-Gupta","year":"2012","unstructured":"Pylayeva-Gupta Y, Lee KE, Hajdu CH, Miller G, Bar-Sagi D. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell. 2012;21:836\u201347.","journal-title":"Cancer Cell"},{"key":"2406_CR31","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.ccr.2012.04.025","volume":"21","author":"LJ Bayne","year":"2012","unstructured":"Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ, et al. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell. 2012;21:822\u201335.","journal-title":"Cancer Cell"},{"key":"2406_CR32","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1136\/gutjnl-2013-306271","volume":"63","author":"IM Stromnes","year":"2014","unstructured":"Stromnes IM, Brockenbrough JS, Izeradjene K, Carlson MA, Cuevas C, Simmons RM, et al. Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut. 2014;63:1769\u201381.","journal-title":"Gut"},{"key":"2406_CR33","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1158\/2326-6066.CIR-15-0241","volume":"4","author":"S Zdanov","year":"2016","unstructured":"Zdanov S, Mandapathil M, Abu Eid R, Adamson-Fadeyi S, Wilson W, Qian J, et al. Mutant KRAS conversion of conventional T cells into regulatory T cells. Cancer Immunol Res. 2016;4:354\u201365.","journal-title":"Cancer Immunol Res"},{"key":"2406_CR34","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1126\/science.275.5308.1943","volume":"275","author":"J Li","year":"1997","unstructured":"Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943\u20137.","journal-title":"Science"},{"key":"2406_CR35","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/nrc3037","volume":"11","author":"MC Hollander","year":"2011","unstructured":"Hollander MC, Blumenthal GM, Dennis PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer. 2011;11:289\u2013301.","journal-title":"Nat Rev Cancer"},{"key":"2406_CR36","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0002-9440(10)64200-9","volume":"161","author":"XP Zhou","year":"2002","unstructured":"Zhou XP, Loukola A, Salovaara R, Nystrom-Lahti M, Peltomaki P, de la Chapelle A, et al. PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol. 2002;161:439\u201347.","journal-title":"Am J Pathol"},{"key":"2406_CR37","doi-asserted-by":"publisher","first-page":"9067","DOI":"10.1073\/pnas.0402932101","volume":"101","author":"AJ Aguirre","year":"2004","unstructured":"Aguirre AJ, Brennan C, Bailey G, Sinha R, Feng B, Leo C, et al. High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci USA. 2004;101:9067\u201372.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2406_CR38","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-15-0224","volume":"6","author":"G Wang","year":"2016","unstructured":"Wang G, Lu X, Dey P, Deng P, Wu CC, Jiang S, et al. Targeting YAP-dependent MDSC infiltration impairs tumor progression. Cancer Disco. 2016;6:80\u201395.","journal-title":"Cancer Disco"},{"key":"2406_CR39","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nature21357","volume":"542","author":"D Zhao","year":"2017","unstructured":"Zhao D, Lu X, Wang G, Lan Z, Liao W, Li J, et al. Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer. Nature. 2017;542:484\u20138.","journal-title":"Nature"},{"key":"2406_CR40","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1158\/2159-8290.CD-19-1352","volume":"10","author":"D Zhao","year":"2020","unstructured":"Zhao D, Cai L, Lu X, Liang X, Li J, Chen P, et al. Chromatin regulator CHD1 remodels the immunosuppressive tumor microenvironment in PTEN-deficient prostate cancer. Cancer Disco. 2020;10:1374\u201387.","journal-title":"Cancer Disco"},{"key":"2406_CR41","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1128\/MCB.00090-14","volume":"34","author":"AJ Garcia","year":"2014","unstructured":"Garcia AJ, Ruscetti M, Arenzana TL, Tran LM, Bianci-Frias D, Sybert E, et al. Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression. Mol Cell Biol. 2014;34:2017\u201328.","journal-title":"Mol Cell Biol"},{"key":"2406_CR42","doi-asserted-by":"publisher","first-page":"7885","DOI":"10.18632\/oncotarget.6955","volume":"7","author":"CW Armstrong","year":"2016","unstructured":"Armstrong CW, Maxwell PJ, Ong CW, Redmond KM, McCann C, Neisen J, et al. PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist\/radiation combination therapy. Oncotarget. 2016;7:7885\u201398.","journal-title":"Oncotarget"},{"key":"2406_CR43","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1016\/j.celrep.2019.07.068","volume":"28","author":"D Di Mitri","year":"2019","unstructured":"Di Mitri D, Mirenda M, Vasilevska J, Calcinotto A, Delaleu N, Revandkar A, et al. Re-education of tumor-associated macrophages by CXCR2 blockade drives senescence and tumor inhibition in advanced prostate cancer. Cell Rep. 2019;28:2156\u201368. e2155","journal-title":"Cell Rep"},{"key":"2406_CR44","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/nature21676","volume":"543","author":"X Lu","year":"2017","unstructured":"Lu X, Horner JW, Paul E, Shang X, Troncoso P, Deng P, et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature. 2017;543:728\u201332.","journal-title":"Nature"},{"key":"2406_CR45","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.ccell.2019.05.003","volume":"35","author":"P Chen","year":"2019","unstructured":"Chen P, Zhao D, Li J, Liang X, Li J, Chang A, et al. Symbiotic macrophage-glioma cell interactions reveal synthetic lethality in PTEN-null glioma. Cancer Cell. 2019;35:868\u201384. e866","journal-title":"Cancer Cell"},{"key":"2406_CR46","doi-asserted-by":"publisher","first-page":"8847","DOI":"10.1073\/pnas.95.15.8847","volume":"95","author":"A de La Coste","year":"1998","unstructured":"de La Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O, et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA. 1998;95:8847\u201351.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2406_CR47","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/onc.2016.304","volume":"36","author":"T Zhan","year":"2017","unstructured":"Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. Oncogene. 2017;36:1461\u201373.","journal-title":"Oncogene"},{"key":"2406_CR48","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1126\/science.275.5307.1784","volume":"275","author":"V Korinek","year":"1997","unstructured":"Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-\/- colon carcinoma. Science. 1997;275:1784\u20137.","journal-title":"Science"},{"key":"2406_CR49","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1158\/2159-8290.CD-21-0680","volume":"12","author":"R Lee","year":"2022","unstructured":"Lee R, Li J, Li J, Wu CJ, Jiang S, Hsu WH. et al. Synthetic essentiality of tryptophan 2,3-dioxygenase 2 in APC-mutated colorectal cancer. Cancer Discov. 2022;12:1702\u20131717.","journal-title":"Cancer Discov"},{"key":"2406_CR50","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.celrep.2015.06.024","volume":"12","author":"E Chun","year":"2015","unstructured":"Chun E, Lavoie S, Michaud M, Gallini CA, Kim J, Soucy G, et al. CCL2 promotes colorectal carcinogenesis by enhancing polymorphonuclear myeloid-derived suppressor cell population and function. Cell Rep. 2015;12:244\u201357.","journal-title":"Cell Rep"},{"key":"2406_CR51","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1172\/JCI43937","volume":"122","author":"M Anson","year":"2012","unstructured":"Anson M, Crain-Denoyelle AM, Baud V, Chereau F, Gougelet A, Terris B, et al. Oncogenic beta-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. J Clin Investig. 2012;122:586\u201399.","journal-title":"J Clin Investig"},{"key":"2406_CR52","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature. 2015;523:231\u20135.","journal-title":"Nature"},{"key":"2406_CR53","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","volume":"31","author":"S Spranger","year":"2017","unstructured":"Spranger S, Dai D, Horton B, Gajewski TF. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell. 2017;31:711\u201323. e714","journal-title":"Cancer Cell"},{"key":"2406_CR54","doi-asserted-by":"publisher","first-page":"E7759","DOI":"10.1073\/pnas.1609376113","volume":"113","author":"S Spranger","year":"2016","unstructured":"Spranger S, Luke JJ, Bao R, Zha Y, Hernandez KM, Li Y, et al. Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma. Proc Natl Acad Sci USA. 2016;113:E7759\u2013E7768.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2406_CR55","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","volume":"25","author":"JJ Luke","year":"2019","unstructured":"Luke JJ, Bao R, Sweis RF, Spranger S, Gajewski TF. WNT\/beta-catenin pathway activation correlates with immune exclusion across human cancers. Clin Cancer Res. 2019;25:3074\u201383.","journal-title":"Clin Cancer Res"},{"key":"2406_CR56","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/nm.1982","volume":"15","author":"L Gattinoni","year":"2009","unstructured":"Gattinoni L, Zhong XS, Palmer DC, Ji Y, Hinrichs CS, Yu Z, et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med. 2009;15:808\u201313.","journal-title":"Nat Med"},{"key":"2406_CR57","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1073\/pnas.1414167112","volume":"112","author":"C Fu","year":"2015","unstructured":"Fu C, Liang X, Cui W, Ober-Blobaum JL, Vazzana J, Shrikant PA, et al. beta-Catenin in dendritic cells exerts opposite functions in cross-priming and maintenance of CD8+ T cells through regulation of IL-10. Proc Natl Acad Sci USA. 2015;112:2823\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2406_CR58","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1158\/0008-5472.CAN-14-2377","volume":"75","author":"Y Hong","year":"2015","unstructured":"Hong Y, Manoharan I, Suryawanshi A, Majumdar T, Angus-Hill ML, Koni PA, et al. beta-catenin promotes regulatory T-cell responses in tumors by inducing vitamin A metabolism in dendritic cells. Cancer Res. 2015;75:656\u201365.","journal-title":"Cancer Res"},{"key":"2406_CR59","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.cell.2017.05.016","volume":"169","author":"R Nusse","year":"2017","unstructured":"Nusse R, Clevers H. Wnt\/beta-catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169:985\u201399.","journal-title":"Cell"},{"key":"2406_CR60","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/310655a0","volume":"310","author":"HA Armelin","year":"1984","unstructured":"Armelin HA, Armelin MC, Kelly K, Stewart T, Leder P, Cochran BH, et al. Functional role for c-myc in mitogenic response to platelet-derived growth factor. Nature. 1984;310:655\u201360.","journal-title":"Nature"},{"key":"2406_CR61","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/0092-8674(83)90092-2","volume":"35","author":"K Kelly","year":"1983","unstructured":"Kelly K, Cochran BH, Stiles CD, Leder P. Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor. Cell. 1983;35:603\u201310.","journal-title":"Cell"},{"key":"2406_CR62","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.cell.2017.11.013","volume":"171","author":"RM Kortlever","year":"2017","unstructured":"Kortlever RM, Sodir NM, Wilson CH, Burkhart DL, Pellegrinet L, Brown Swigart L, et al. Myc cooperates with Ras by programming inflammation and immune suppression. Cell. 2017;171:1301\u201315. e1314","journal-title":"Cell"},{"key":"2406_CR63","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1101\/gad.2038411","volume":"25","author":"NM Sodir","year":"2011","unstructured":"Sodir NM, Swigart LB, Karnezis AN, Hanahan D, Evan GI, Soucek L. Endogenous Myc maintains the tumor microenvironment. Genes Dev. 2011;25:907\u201316.","journal-title":"Genes Dev"},{"key":"2406_CR64","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1158\/1078-0432.CCR-16-2128","volume":"23","author":"D Balli","year":"2017","unstructured":"Balli D, Rech AJ, Stanger BZ, Vonderheide RH. Immune cytolytic activity stratifies molecular subsets of human pancreatic cancer. Clin Cancer Res. 2017;23:3129\u201338.","journal-title":"Clin Cancer Res"},{"key":"2406_CR65","doi-asserted-by":"publisher","first-page":"e1320626","DOI":"10.1080\/2162402X.2017.1320626","volume":"6","author":"JP Layer","year":"2017","unstructured":"Layer JP, Kronmuller MT, Quast T, van den Boorn-Konijnenberg D, Effern M, Hinze D, et al. Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression. Oncoimmunology. 2017;6:e1320626.","journal-title":"Oncoimmunology"},{"key":"2406_CR66","doi-asserted-by":"publisher","first-page":"e1316439","DOI":"10.1080\/2162402X.2017.1316439","volume":"6","author":"E Brandetti","year":"2017","unstructured":"Brandetti E, Veneziani I, Melaiu O, Pezzolo A, Castellano A, Boldrini R, et al. MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma. Oncoimmunology. 2017;6:e1316439.","journal-title":"Oncoimmunology"},{"key":"2406_CR67","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.18632\/oncotarget.2969","volume":"6","author":"A Yetil","year":"2015","unstructured":"Yetil A, Anchang B, Gouw AM, Adam SJ, Zabuawala T, Parameswaran R, et al. p19ARF is a critical mediator of both cellular senescence and an innate immune response associated with MYC inactivation in mouse model of acute leukemia. Oncotarget. 2015;6:3563\u201377.","journal-title":"Oncotarget"},{"key":"2406_CR68","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrc2723","volume":"9","author":"AJ Levine","year":"2009","unstructured":"Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer. 2009;9:749\u201358.","journal-title":"Nat Rev Cancer"},{"key":"2406_CR69","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","volume":"170","author":"ER Kastenhuber","year":"2017","unstructured":"Kastenhuber ER, Lowe SW. Putting p53 in context. Cell. 2017;170:1062\u201378.","journal-title":"Cell"},{"key":"2406_CR70","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/nm.4463","volume":"24","author":"M Bezzi","year":"2018","unstructured":"Bezzi M, Seitzer N, Ishikawa T, Reschke M, Chen M, Wang G, et al. Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms. Nat Med. 2018;24:165\u201375.","journal-title":"Nat Med"},{"key":"2406_CR71","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/s41586-019-1450-6","volume":"572","author":"MD Wellenstein","year":"2019","unstructured":"Wellenstein MD, Coffelt SB, Duits DEM, van Miltenburg MH, Slagter M, de Rink I, et al. Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis. Nature. 2019;572:538\u201342.","journal-title":"Nature"},{"key":"2406_CR72","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41418-018-0126-3","volume":"26","author":"SW Ham","year":"2019","unstructured":"Ham SW, Jeon HY, Jin X, Kim EJ, Kim JK, Shin YJ, et al. TP53 gain-of-function mutation promotes inflammation in glioblastoma. Cell Death Differ. 2019;26:409\u201325.","journal-title":"Cell Death Differ"},{"key":"2406_CR73","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ccr.2012.11.014","volume":"23","author":"S Schwitalla","year":"2013","unstructured":"Schwitalla S, Ziegler PK, Horst D, Becker V, Kerle I, Begus-Nahrmann Y, et al. Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors. Cancer Cell. 2013;23:93\u2013106.","journal-title":"Cancer Cell"},{"key":"2406_CR74","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.ccr.2013.03.022","volume":"23","author":"T Cooks","year":"2013","unstructured":"Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, et al. Mutant p53 prolongs NF-kappaB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell. 2013;23:634\u201346.","journal-title":"Cancer Cell"},{"key":"2406_CR75","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1053\/j.gastro.2016.03.010","volume":"151","author":"SM Wormann","year":"2016","unstructured":"Wormann SM, Song L, Ai J, Diakopoulos KN, Kurkowski MU, Gorgulu K, et al. Loss of P53 function activates JAK2-STAT3 signaling to promote pancreatic tumor growth, stroma modification, and gemcitabine resistance in mice and is associated with patient survival. Gastroenterology. 2016;151:180\u201393. e112","journal-title":"Gastroenterology"},{"key":"2406_CR76","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.celrep.2019.12.028","volume":"30","author":"J Blagih","year":"2020","unstructured":"Blagih J, Zani F, Chakravarty P, Hennequart M, Pilley S, Hobor S, et al. Cancer-specific loss of p53 leads to a modulation of myeloid and T cell responses. Cell Rep. 2020;30:481\u201396. e486","journal-title":"Cell Rep"},{"key":"2406_CR77","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.cell.2013.03.020","volume":"153","author":"A Lujambio","year":"2013","unstructured":"Lujambio A, Akkari L, Simon J, Grace D, Tschaharganeh DF, Bolden JE, et al. Non-cell-autonomous tumor suppression by p53. Cell. 2013;153:449\u201360.","journal-title":"Cell"},{"key":"2406_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03224-w","volume":"9","author":"T Cooks","year":"2018","unstructured":"Cooks T, Pateras IS, Jenkins LM, Patel KM, Robles AI, Morris J, et al. Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246. Nat Commun. 2018;9:771.","journal-title":"Nat Commun"},{"key":"2406_CR79","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1158\/1078-0432.CCR-08-1283","volume":"15","author":"AH Beck","year":"2009","unstructured":"Beck AH, Espinosa I, Edris B, Li R, Montgomery K, Zhu S, et al. The macrophage colony-stimulating factor 1 response signature in breast carcinoma. Clin Cancer Res. 2009;15:778\u201387.","journal-title":"Clin Cancer Res"},{"key":"2406_CR80","doi-asserted-by":"crossref","unstructured":"Maddalena M, Mallel G, Nataraj NB, Shreberk-Shaked M, Hassin O, Mukherjee S, et al. TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment. Proc Natl Acad Sci USA. 2021;118.","DOI":"10.1073\/pnas.2025631118"},{"key":"2406_CR81","doi-asserted-by":"publisher","first-page":"109578","DOI":"10.1016\/j.celrep.2021.109578","volume":"36","author":"D Siolas","year":"2021","unstructured":"Siolas D, Vucic E, Kurz E, Hajdu C, Bar-Sagi D. Gain-of-function p53(R172H) mutation drives accumulation of neutrophils in pancreatic tumors, promoting resistance to immunotherapy. Cell Rep. 2021;36:109578.","journal-title":"Cell Rep"},{"key":"2406_CR82","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1742-4658.2009.07448.x","volume":"277","author":"T Mitsudomi","year":"2010","unstructured":"Mitsudomi T, Yatabe Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J. 2010;277:301\u20138.","journal-title":"FEBS J"},{"key":"2406_CR83","doi-asserted-by":"publisher","first-page":"4493","DOI":"10.4049\/jimmunol.1600576","volume":"197","author":"SE Busch","year":"2016","unstructured":"Busch SE, Hanke ML, Kargl J, Metz HE, MacPherson D, Houghton AM. Lung cancer subtypes generate unique immune responses. J Immunol. 2016;197:4493\u2013503.","journal-title":"J Immunol"},{"key":"2406_CR84","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","volume":"3","author":"EA Akbay","year":"2013","unstructured":"Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013;3:1355\u201363.","journal-title":"Cancer Discov"},{"key":"2406_CR85","doi-asserted-by":"crossref","unstructured":"Sugiyama E, Togashi Y, Takeuchi Y, Shinya S, Tada Y, Kataoka K, et al. Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer. Sci Immunol. 2020; 5.","DOI":"10.1126\/sciimmunol.aav3937"},{"key":"2406_CR86","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1158\/1078-0432.CCR-15-2597","volume":"23","author":"DH Wang","year":"2017","unstructured":"Wang DH, Lee HS, Yoon D, Berry G, Wheeler TM, Sugarbaker DJ, et al. Progression of EGFR-mutant lung adenocarcinoma is driven by Alveolar macrophages. Clin Cancer Res. 2017;23:778\u201388.","journal-title":"Clin Cancer Res"},{"key":"2406_CR87","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1158\/0008-5472.CAN-17-3551","volume":"78","author":"Z An","year":"2018","unstructured":"An Z, Knobbe-Thomsen CB, Wan X, Fan QW, Reifenberger G, Weiss WA. EGFR cooperates with EGFRvIII to recruit macrophages in glioblastoma. Cancer Res. 2018;78:6785\u201394.","journal-title":"Cancer Res"},{"key":"2406_CR88","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.1172\/JCI82152","volume":"125","author":"CG Pena","year":"2015","unstructured":"Pena CG, Nakada Y, Saatcioglu HD, Aloisio GM, Cuevas I, Zhang S, et al. LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment. J Clin Investig. 2015;125:4063\u201376.","journal-title":"J Clin Investig"},{"key":"2406_CR89","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1158\/0008-5472.CAN-15-1439","volume":"76","author":"S Koyama","year":"2016","unstructured":"Koyama S, Akbay EA, Li YY, Aref AR, Skoulidis F, Herter-Sprie GS, et al. STK11\/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment. Cancer Res. 2016;76:999\u20131008.","journal-title":"Cancer Res"},{"key":"2406_CR90","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.ccr.2014.03.033","volume":"25","author":"C Xu","year":"2014","unstructured":"Xu C, Fillmore CM, Koyama S, Wu H, Zhao Y, Chen Z, et al. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell. 2014;25:590\u2013604.","journal-title":"Cancer Cell"},{"key":"2406_CR91","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41586-019-1049-y","volume":"568","author":"CL Eng","year":"2019","unstructured":"Eng CL, Lawson M, Zhu Q, Dries R, Koulena N, Takei Y, et al. Transcriptome-scale super-resolved imaging in tissues by RNA seqFISH. Nature. 2019;568:235\u20139.","journal-title":"Nature"},{"key":"2406_CR92","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/nmeth.2892","volume":"11","author":"E Lubeck","year":"2014","unstructured":"Lubeck E, Coskun AF, Zhiyentayev T, Ahmad M, Cai L. Single-cell in situ RNA profiling by sequential hybridization. Nat Methods. 2014;11:360\u20131.","journal-title":"Nat Methods"},{"key":"2406_CR93","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaw1219","volume":"363","author":"SG Rodriques","year":"2019","unstructured":"Rodriques SG, Stickels RR, Goeva A, Martin CA, Murray E, Vanderburg CR, et al. Slide-seq: a scalable technology for measuring genome-wide expression at high spatial resolution. Science. 2019;363:1463\u20137.","journal-title":"Science"},{"key":"2406_CR94","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.1016\/j.cell.2021.09.022","volume":"184","author":"BT Grunwald","year":"2021","unstructured":"Grunwald BT, Devisme A, Andrieux G, Vyas F, Aliar K, McCloskey CW, et al. Spatially confined sub-tumor microenvironments in pancreatic cancer. Cell. 2021;184:5577\u201392. e5518","journal-title":"Cell"},{"key":"2406_CR95","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.cell.2019.05.012","volume":"178","author":"M Ligorio","year":"2019","unstructured":"Ligorio M, Sil S, Malagon-Lopez J, Nieman LT, Misale S, Di Pilato M, et al. Stromal microenvironment shapes the intratumoral architecture of pancreatic cancer. Cell. 2019;178:160\u201375. e127","journal-title":"Cell"},{"key":"2406_CR96","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/s41591-020-0900-x","volume":"26","author":"K AbdulJabbar","year":"2020","unstructured":"AbdulJabbar K, Raza SEA, Rosenthal R, Jamal-Hanjani M, Veeriah S, Akarca A, et al. Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. Nat Med. 2020;26:1054\u201362.","journal-title":"Nat Med"},{"key":"2406_CR97","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.trecan.2019.07.006","volume":"5","author":"BL Horton","year":"2019","unstructured":"Horton BL, Fessenden TB, Spranger S. Tissue site and the cancer immunity cycle. Trends Cancer. 2019;5:593\u2013603.","journal-title":"Trends Cancer"},{"key":"2406_CR98","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.it.2019.02.003","volume":"40","author":"P Pathria","year":"2019","unstructured":"Pathria P, Louis TL, Varner JA. Targeting tumor-associated macrophages in cancer. Trends Immunol. 2019;40:310\u201327.","journal-title":"Trends Immunol"},{"key":"2406_CR99","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","volume":"19","author":"DG DeNardo","year":"2019","unstructured":"DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 2019;19:369\u201382.","journal-title":"Nat Rev Immunol"},{"key":"2406_CR100","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nrc3581","volume":"13","author":"JE Talmadge","year":"2013","unstructured":"Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer. 2013;13:739\u201352.","journal-title":"Nat Rev Cancer"},{"key":"2406_CR101","doi-asserted-by":"publisher","first-page":"107556","DOI":"10.1016\/j.pharmthera.2020.107556","volume":"212","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Rahmy S, Liu Z, Zhang C, Lu X. Rational targeting of immunosuppressive neutrophils in cancer. Pharm Ther. 2020;212:107556.","journal-title":"Pharm Ther"},{"key":"2406_CR102","doi-asserted-by":"publisher","first-page":"36.","DOI":"10.3390\/vaccines4040036","volume":"4","author":"V Umansky","year":"2016","unstructured":"Umansky V, Blattner C, Gebhardt C, Utikal J. The role of myeloid-derived suppressor cells (MDSC) in cancer progression. Vaccines. 2016;4:36.","journal-title":"Vaccines"},{"key":"2406_CR103","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41586-020-2394-6","volume":"583","author":"L Yang","year":"2020","unstructured":"Yang L, Liu Q, Zhang X, Liu X, Zhou B, Chen J, et al. DNA of neutrophil extracellular traps promotes cancer metastasis via CCDC25. Nature. 2020;583:133\u20138.","journal-title":"Nature"},{"key":"2406_CR104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41423-019-0306-1","volume":"17","author":"K Nakamura","year":"2020","unstructured":"Nakamura K, Smyth MJ. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell Mol Immunol. 2020;17:1\u201312.","journal-title":"Cell Mol Immunol"},{"key":"2406_CR105","doi-asserted-by":"publisher","first-page":"9012369","DOI":"10.1155\/2016\/9012369","volume":"2016","author":"B Sainz Jr.","year":"2016","unstructured":"Sainz B Jr., Carron E, Vallespinos M, Machado HL. Cancer stem cells and macrophages: implications in tumor biology and therapeutic strategies. Mediators Inflamm. 2016;2016:9012369.","journal-title":"Mediators Inflamm"},{"key":"2406_CR106","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1172\/JCI133055","volume":"130","author":"B Theivanthiran","year":"2020","unstructured":"Theivanthiran B, Evans KS, DeVito NC, Plebanek M, Sturdivant M, Wachsmuth LP, et al. A tumor-intrinsic PD-L1\/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy. J Clin Investig. 2020;130:2570\u201386.","journal-title":"J Clin Investig"},{"key":"2406_CR107","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/j.jid.2017.03.033","volume":"137","author":"SH Kim","year":"2017","unstructured":"Kim SH, Li M, Trousil S, Zhang Y, Pasca di Magliano M, Swanson KD, et al. Phenformin inhibits myeloid-derived suppressor cells and enhances the anti-tumor activity of PD-1 blockade in melanoma. J Invest Dermatol. 2017;137:1740\u20138.","journal-title":"J Invest Dermatol"},{"key":"2406_CR108","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","volume":"6","author":"W Peng","year":"2016","unstructured":"Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 2016;6:202\u201316.","journal-title":"Cancer Discov"},{"key":"2406_CR109","doi-asserted-by":"crossref","unstructured":"Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017;9.","DOI":"10.1126\/scitranslmed.aah3560"},{"key":"2406_CR110","doi-asserted-by":"publisher","first-page":"237ra267","DOI":"10.1126\/scitranslmed.3007974","volume":"6","author":"SL Highfill","year":"2014","unstructured":"Highfill SL, Cui Y, Giles AJ, Smith JP, Zhang H, Morse E, et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med. 2014;6:237ra267.","journal-title":"Sci Transl Med"},{"key":"2406_CR111","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","volume":"74","author":"Y Zhu","year":"2014","unstructured":"Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, et al. CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014;74:5057\u201369.","journal-title":"Cancer Res"},{"key":"2406_CR112","doi-asserted-by":"crossref","unstructured":"Neubert NJ, Schmittnaegel M, Bordry N, Nassiri S, Wald N, Martignier C. et al. T cell-induced CSF1 promotes melanoma resistance to PD1 blockade. Sci Transl Med. 2018;10.","DOI":"10.1126\/scitranslmed.aan3311"},{"key":"2406_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-42237-3","volume":"9","author":"T Knox","year":"2019","unstructured":"Knox T, Sahakian E, Banik D, Hadley M, Palmer E, Noonepalle S, et al. Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells. Sci Rep. 2019;9:6136.","journal-title":"Sci Rep"},{"key":"2406_CR114","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nature21409","volume":"543","author":"JL Guerriero","year":"2017","unstructured":"Guerriero JL, Sotayo A, Ponichtera HE, Castrillon JA, Pourzia AL, Schad S, et al. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages. Nature. 2017;543:428\u201332.","journal-title":"Nature"},{"key":"2406_CR115","doi-asserted-by":"crossref","unstructured":"Kargl J, Zhu X, Zhang H, Yang GHY, Friesen TJ, Shipley M, et al. Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC. JCI Insight. 2019; 4.","DOI":"10.1172\/jci.insight.130850"},{"key":"2406_CR116","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.1016\/j.celrep.2017.11.052","volume":"21","author":"J Faget","year":"2017","unstructured":"Faget J, Groeneveld S, Boivin G, Sankar M, Zangger N, Garcia M, et al. Neutrophils and snail orchestrate the establishment of a pro-tumor microenvironment in lung cancer. Cell Rep. 2017;21:3190\u2013204.","journal-title":"Cell Rep"},{"key":"2406_CR117","doi-asserted-by":"publisher","first-page":"e0166626","DOI":"10.1371\/journal.pone.0166626","volume":"11","author":"H Sumimoto","year":"2016","unstructured":"Sumimoto H, Takano A, Teramoto K, Daigo Y. RAS-mitogen-activated protein kinase signal is required for enhanced PD-L1 expression in human lung cancers. PLoS One. 2016;11:e0166626.","journal-title":"PLoS One"},{"key":"2406_CR118","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.immuni.2017.11.016","volume":"47","author":"MA Coelho","year":"2017","unstructured":"Coelho MA, de Carne Trecesson S, Rana S, Zecchin D, Moore C, Molina-Arcas M, et al. Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA. Immunity. 2017;47:1083\u201399. e1086","journal-title":"Immunity"},{"key":"2406_CR119","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.canlet.2019.10.027","volume":"470","author":"C Liu","year":"2020","unstructured":"Liu C, Zheng S, Jin R, Wang X, Wang F, Zang R, et al. The superior efficacy of anti-PD-1\/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. Cancer Lett. 2020;470:95\u2013105.","journal-title":"Cancer Lett"},{"key":"2406_CR120","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","volume":"16","author":"K Ganesh","year":"2019","unstructured":"Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16:361\u201375.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2406_CR121","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/ags3.12176","volume":"2","author":"RJ Torphy","year":"2018","unstructured":"Torphy RJ, Zhu Y, Schulick RD. Immunotherapy for pancreatic cancer: barriers and breakthroughs. Ann Gastroenterol Surg. 2018;2:274\u201381.","journal-title":"Ann Gastroenterol Surg"},{"key":"2406_CR122","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/2159-8290.CD-18-0689","volume":"9","author":"S Kitajima","year":"2019","unstructured":"Kitajima S, Ivanova E, Guo S, Yoshida R, Campisi M, Sundararaman SK, et al. Suppression of STING associated with LKB1 loss in KRAS-driven lung cancer. Cancer Disco. 2019;9:34\u201345.","journal-title":"Cancer Disco"},{"key":"2406_CR123","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nm1517","volume":"13","author":"AT Parsa","year":"2007","unstructured":"Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007;13:84\u201388.","journal-title":"Nat Med"},{"key":"2406_CR124","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41591-019-0349-y","volume":"25","author":"J Zhao","year":"2019","unstructured":"Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med. 2019;25:462\u20139.","journal-title":"Nat Med"},{"key":"2406_CR125","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.immuni.2017.02.001","volume":"46","author":"S George","year":"2017","unstructured":"George S, Miao D, Demetri GD, Adeegbe D, Rodig SJ, Shukla S, et al. Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma. Immunity. 2017;46:197\u2013204.","journal-title":"Immunity"},{"key":"2406_CR126","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1016\/j.bbrc.2018.08.037","volume":"503","author":"AM Hlaing","year":"2018","unstructured":"Hlaing AM, Furusato B, Udo E, Kitamura Y, Souda M, Masutani M, et al. Expression of phosphatase and tensin homolog and programmed cell death ligand 1 in adenosquamous carcinoma of the lung. Biochem Biophys Res Commun. 2018;503:2764\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"2406_CR127","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.lungcan.2019.03.012","volume":"131","author":"KM Kerr","year":"2019","unstructured":"Kerr KM, Thunnissen E, Dafni U, Finn SP, Bubendorf L, Soltermann A, et al. A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project. Lung Cancer. 2019;131:95\u2013103.","journal-title":"Lung Cancer"},{"key":"2406_CR128","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.21873\/anticanres.12662","volume":"38","author":"M Bassanelli","year":"2018","unstructured":"Bassanelli M, Sioletic S, Martini M, Giacinti S, Viterbo A, Staddon A, et al. Heterogeneity of PD-L1 expression and relationship with biology of NSCLC. Anticancer Res. 2018;38:3789\u201396.","journal-title":"Anticancer Res"},{"key":"2406_CR129","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/annonc\/mdw436","volume":"28","author":"H Kadara","year":"2017","unstructured":"Kadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, et al. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Ann Oncol. 2017;28:75\u201382.","journal-title":"Ann Oncol"},{"key":"2406_CR130","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/annonc\/mdu242","volume":"25","author":"K Azuma","year":"2014","unstructured":"Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, Harada T, et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol. 2014;25:1935\u201340.","journal-title":"Ann Oncol"},{"key":"2406_CR131","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1097\/JTO.0000000000000500","volume":"10","author":"N Chen","year":"2015","unstructured":"Chen N, Fang W, Zhan J, Hong S, Tang Y, Kang S, et al. Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-Driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation. J Thorac Oncol. 2015;10:910\u201323.","journal-title":"J Thorac Oncol"},{"key":"2406_CR132","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/annonc\/mdw437","volume":"28","author":"M Choi","year":"2017","unstructured":"Choi M, Kadara H, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, et al. Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. Ann Oncol. 2017;28:83\u201389.","journal-title":"Ann Oncol"},{"key":"2406_CR133","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1080\/14740338.2017.1300656","volume":"16","author":"MJ Ahn","year":"2017","unstructured":"Ahn MJ, Sun JM, Lee SH, Ahn JS, Park K. EGFR TKI combination with immunotherapy in non-small cell lung cancer. Expert Opin Drug Saf. 2017;16:465\u20139.","journal-title":"Expert Opin Drug Saf"},{"key":"2406_CR134","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","volume":"8","author":"F Skoulidis","year":"2018","unstructured":"Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, et al. STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Disco. 2018;8:822\u201335.","journal-title":"Cancer Disco"},{"key":"2406_CR135","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41392-021-00534-2","volume":"6","author":"H Liu","year":"2021","unstructured":"Liu H, Liang Z, Zhou C, Zeng Z, Wang F, Hu T, et al. Mutant KRAS triggers functional reprogramming of tumor-associated macrophages in colorectal cancer. Signal Transduct Target Ther. 2021;6:144.","journal-title":"Signal Transduct Target Ther"},{"key":"2406_CR136","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ccell.2022.01.003","volume":"40","author":"A Alam","year":"2022","unstructured":"Alam A, Levanduski E, Denz P, Villavicencio HS, Bhatta M, Alhorebi L, et al. Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer. Cancer Cell. 2022;40:153\u201367. e111","journal-title":"Cancer Cell"},{"key":"2406_CR137","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.ccell.2016.04.014","volume":"29","author":"CW Steele","year":"2016","unstructured":"Steele CW, Karim SA, Leach JDG, Bailey P, Upstill-Goddard R, Rishi L, et al. CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell. 2016;29:832\u201345.","journal-title":"Cancer Cell"},{"key":"2406_CR138","first-page":"411","volume":"16","author":"A Dart","year":"2016","unstructured":"Dart A. Metastasis: CXCR2-targeted therapy for pancreatic cancer. Nat Rev Cancer. 2016;16:411.","journal-title":"Nat Rev Cancer"},{"key":"2406_CR139","doi-asserted-by":"crossref","unstructured":"Li Y, He Y, Butler W, Xu L, Chang Y, Lei K, et al. Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer. Sci Transl Med. 2019;11.","DOI":"10.1126\/scitranslmed.aax0428"},{"key":"2406_CR140","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.bbcan.2019.01.005","volume":"1871","author":"Y Cheng","year":"2019","unstructured":"Cheng Y, Ma XL, Wei YQ, Wei XW. Potential roles and targeted therapy of the CXCLs\/CXCR2 axis in cancer and inflammatory diseases. Biochim Biophys Acta Rev Cancer. 2019;1871:289\u2013312.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2406_CR141","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s10637-018-0580-2","volume":"36","author":"H Hurwitz","year":"2018","unstructured":"Hurwitz H, Van Cutsem E, Bendell J, Hidalgo M, Li CP, Salvo MG, et al. Ruxolitinib + capecitabine in advanced\/metastatic pancreatic cancer after disease progression\/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies. Investig N Drugs. 2018;36:683\u201395.","journal-title":"Investig N Drugs"},{"key":"2406_CR142","first-page":"75","volume":"8","author":"LA Raedler","year":"2015","unstructured":"Raedler LA. Jakafi (Ruxolitinib): first FDA-approved medication for the treatment of patients with polycythemia Vera. Am Health Drug Benefits. 2015;8:75\u201379.","journal-title":"Am Health Drug Benefits"},{"key":"2406_CR143","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/nrc.2017.117","volume":"18","author":"S Spranger","year":"2018","unstructured":"Spranger S, Gajewski TF. Impact of oncogenic pathways on evasion of antitumour immune responses. Nat Rev Cancer. 2018;18:139\u201347.","journal-title":"Nat Rev Cancer"},{"key":"2406_CR144","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","volume":"371","author":"D Davar","year":"2021","unstructured":"Davar D, Dzutsev AK, McCulloch JA, Rodrigues RR, Chauvin JM, Morrison RM, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021;371:595\u2013602.","journal-title":"Science"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-022-02406-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-022-02406-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-022-02406-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T08:08:53Z","timestamp":1659082133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-022-02406-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,11]]},"references-count":144,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2022,7,29]]}},"alternative-id":["2406"],"URL":"https:\/\/doi.org\/10.1038\/s41388-022-02406-7","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,11]]},"assertion":[{"value":"19 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PD has a patent pending on targeting IL-33 in cancer (U.S. Provisional Patent Application, Serial No. 63\/238,531). PC has nothing to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}